What is NovaScan?
Headquartered in Chicago, Illinois, NovaScan operates at the intersection of biotechnology and medical device engineering. The company is dedicated to pioneering a new, low-cost point-of-care platform designed to revolutionize cancer detection and treatment protocols. By focusing on scalable, science-led solutions, NovaScan addresses the urgent need for accessible diagnostic tools that can be deployed in diverse clinical environments. Its market position is defined by a commitment to precision health, aiming to reduce the barriers to early cancer intervention through technological disruption and rigorous clinical methodology.
How much funding has NovaScan raised?
NovaScan has raised a total of $8M across 1 funding round:
Series B
$8M
Series B (2021): $8M with participation from BioPacific Investors, Gore Range Capital, Dipalo Ventures, Harvard Business School Alumni Angels of Chicago, Stateline Angels, and Builders VC
Key Investors in NovaScan
Gore Range Capital
Gore Range Capital is a venture capital firm specializing in early-stage healthcare investments, focusing on science-led platforms in precision health, regenerative medicine, and personalized therapeutics.
Dipalo Ventures
Dipalo Ventures invests in early-stage, breakthrough deep tech innovations that are transforming the future of energy, climate, and physical AI by providing product expertise and engineering knowledge.
Harvard Business School Alumni Angels of Chicago
The Harvard Business School Alumni Angels of Chicago is an organization that enables angel investors to support early-stage ventures in the Chicago area through capital and mentorship.
What's next for NovaScan?
Looking ahead, NovaScan is poised to leverage its recent capital injection to scale its operational capabilities and expand its clinical trial footprint. The strategic focus will likely center on refining its diagnostic platform to meet regulatory milestones while simultaneously building out the infrastructure necessary for commercial deployment. As the company moves deeper into its clinical-stage lifecycle, the emphasis will shift toward establishing strategic partnerships with healthcare providers and integrating its technology into existing oncology workflows. This trajectory suggests a robust growth phase, with the firm prioritizing the translation of its scientific innovations into tangible, life-saving clinical outcomes.
See full NovaScan company page
